All News

There is still work to do in the field of molecular diagnosis for renal cell carcinoma, according to David I. Quinn, MBBS, Ph.D., FRACP, FACP.

In metastatic breast cancer, the brain MRI is often a special request for what you don't want but truly need.

Making the shift from survivor to 'thriver' is challenging. In this post, learn how one survivor makes the change.

The Food and Drug Administration (FDA) Expanded Access program appeared to have broad use, involved a wide variety of patients and drugs, and derived clinical benefit, according to an initial summary published in JAMA Oncology.

This cancer survivor finds a hidden treasure in death and dying.

Debu Tripathy, M.D., the editor in chief of CURE®, recently sat down at the Miami Breast Cancer Conference to discuss the importance of oncology nurses in breast cancer care and offered insight as to how they can keep up-to-date with the constant advancements in the field.

From fertility research developments for childhood cancer to today’s top performers and entertainers, here’s what’s making headlines in the cancer space this week.

Many children with cancer participate in clinical trials. Perhaps little children should be leading us more often in health care?

How being treated for an allergy to cats and persistence finally led to my diagnoses of Hodgkin's lymphoma.

"We hope these thoughts on the prevention of, and awareness about, GI cancers and their side effects will be helpful to patients, survivors and caregivers alike," says CEO and Chairman Mike Hennessy, Sr.

Did we bring this scary, painful, financially draining monster into our lives by eating too many cookies and not doing enough jumping jacks? We need a reliable diagnostic screening tool for ovarian cancer and we need it now.

Surprise! You can’t believe everything you read on the internet!

Adam Brufsky, M.D., Ph.D. discussed treatments for BRCA-positive breast cancer at the 2019 Miami Breast Cancer Conference.

"How worried 'should' I be?", ponders one cancer survivor.

Lenvima (lenvatinib) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, according to results from a phase I study.

A hospital whose mission is to cure children’s catastrophic diseases is not only providing treatment, but also conducting research and making new medicines. Now, in addition to improving its patient-care and research capabilities, it plans to reach into low-income countries to help cure more children with cancer.

Anemia is so intertwined with cancer that every current patient and survivor should know about it.

During the 2019 Miami Breast Cancer Conference, an expert discussed financial toxicity and the role of healthcare providers in addressing the cost of care with their patients.

Fourth-generation, family-owned egg and feed farm joins local cycling event to achieve Victory Over Cancer®.

Treatment with the combination of Keytruda (pembrolizumab), Avastin (bevacizumab) and metronomic cyclophosphamide appeared safe and effective in women with recurrent epithelial ovarian cancer, according to results from an open-label phase 2 study.

How to build good self-care habits for a better life with cancer.

Immune checkpoint inhibitors were generally well tolerated and may be a viable treatment option for patients with HIV infection and advanced-stage cancer.

Team V raises thousands to support cancer research.

The Food and Drug Administration (FDA) has granted an approval to the combination of Tecentriq (atezolizumab) with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

On March 9th , CURE® held the first patient portion of the 36th Annual Miami Breast Cancer Conference and I was gratefully in attendance.

Breast cancer is no laughing matter, but being able to find something to laugh about in the midst of the trial can be cathartic.

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, meaning repeat use could become more common.

Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose.

Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced longer progression-free survival, as well as more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial.

Of all the things that cancer left me with, scarred veins in my only good arm has been the worst. I have learned to treasure those techs who can find a good vein and hit it the first time.